The correlation and pathogenesis of estrogen, vitamin D and bone formation related protein in osteoporosis and cardiovascular,cerebrovascular artery calcification.
Zhou Rui*, Xu Jianzhong, Zhou Huadong.
*Department of Orthopedic, the Orthopedic Surgery Center of Chinese PLA, Southwest Hospital, the Third Military Medical University, Chongqing 400038, China
Abstract：Objective To explore the correlation and pathogenesis of estrogen, vitamin D and bone formation related protein in osteoporosis, cardiovascular and cerebrovascular artery calcification.Methods Literatures about the relationship between estrogen, vitamin D deficiency and bone formation related protein and osteoporosis or vascular calcification plaque from January 1995 to September 2015 in PubMed and CNKI with the key words "estrogen, vitamin D, bone formation related protein, osteoporosis and vascular calcification plaque" were selected. The correlation between osteoporosis and the formation of calcified plaque were analyzed and summarized.Results Both estrogen deficiency and vitamin D deficiency had close relationship with osteoporosis and vascular calcification plaque. Osteoprotegerin, adiponectin, bone morphogenetic protein and osteopontin were important cytokines for pathogenesis of osteoporosis associated with vascular calcification plaque.Conclusions Research on the pathogenesis of estrogen, vitamin D and bone formation related protein associated with osteoporosis, cardiovascular and cerebrovascular artery calcification is important for prevention and control of elderly chronic diseases like cardiovascular system diseases and osteoporosis.
周锐, 许建中, 周华东. 雌激素、维生素D 和骨形态发生蛋白质与骨质疏松症及心脑动脉钙化的发生机制[J]. 中华解剖与临床杂志, 2017, 22(1): 83-86.
Zhou Rui, Xu Jianzhong, Zhou Huadong.. The correlation and pathogenesis of estrogen, vitamin D and bone formation related protein in osteoporosis and cardiovascular,cerebrovascular artery calcification.. Chinese Journal of Anatomy and Clinics, 2017, 22(1): 83-86.
Cosman F, Crittenden DB, Adachi JD, et al. Romosozumab treatment in postmenopausal women with osteoporosis[J]. N Engl J Med, 2016, 375(16): 1532-1543. DOI:10.1056/NEJMoa1607948
Kalogeropoulos AP, Georgiopoulou VV, Murphy RA, et al. Dietary sodium content, mortality, and risk for cardiovascular events in older adults: the Health, Aging, and Body Composition (Health ABC) Study[J]. JAMA Intern Med, 2015, 175(3): 410-419. DOI:10.1001/jamainternmed.2014.6278
[4]
Sprini D, Rini GB, Di Stefano L, et al. Correlation between osteoporosis and cardiovascular disease[J]. Clin Cases Miner Bone Metab, 2014, 11(2): 117-119. DOI:10.11138/ccmbm/2014.11.2.117
[5]
White J, Wilson G, Tucci MA, et al. The effects of sustained delivery of estrogen on bone strength and cardiovascular panels in osteoporotic female rats[J]. Biomed Sci Instrum, 2014, 50: 336-344
[6]
Lindsay R, Gallagher JC, Kleerekoper M, et al. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women[J]. JAMA, 2002, 287(20): 2668-2676. DOI:10.1001/jama.287.20.2668
[7]
Gambacciani M, Levancini M. Management of postmenopausal osteoporosis and the prevention of fractures[J]. Panminerva Med, 2014, 56(2): 115-131
Manson JE, Allison MA, Rossouw JE, et al. Estrogen therapy and coronary-artery calcification[J]. N Engl J Med, 2007, 356(25): 2591-2602. DOI:10.1056/NEJMoa071513
[10]
Fitzpatrick LA. Gender-related differences in the development of atherosclerosis: studies at the cellular level[J]. Clin Exp Pharmacol Physiol, 1996, 23(3): 267-269. DOI:10.1111/j.1440-1681.1996.tb02609.x
[11]
Messalli EM, Mainini G, Scaffa C, et al. Raloxifene therapy interacts with serum osteoprotegerin in postmenopausal women[J]. Maturitas, 2007, 56(1): 38-44. DOI:10.1016/j.maturitas.2006.05.007
[12]
Quintero-Platt G, González-Reimers E, Martín-González MC, et al. Vitamin D, vascular calcification and mortality among alcoholics[J]. Alcohol Alcohol, 2015, 50(1): 18-23. DOI:10.1093/alcalc/agu076
Cauley JA, Greendale GA, Ruppert K, et al. Serum 25 hydroxyvitamin D, bone mineral density and fracture risk across the menopause[J]. J Clin Endocrinol Metab, 2015, 100(5): 2046-2054. DOI:10.1210/jc.2014-4367
[15]
de Boer IH, Kestenbaum B, Shoben AB, et al. 25-hydroxyvitamin D levels inversely associate with risk for developing coronary artery calcification[J]. J Am Soc Nephrol, 2009, 20(8): 1805-1812. DOI:10.1681/ASN.2008111157
[16]
Okano T. Bone metabolism and cardiovascular function update. Role of vitamin D in the bone and vascular intercommunication[J]. Clin Calcium, 2014, 24(7): 45-52. DOI:CliCa140710131020
[17]
Brincat M, Gambin J, Brincat M, et al. The role of vitamin D in osteoporosis[J]. Maturitas, 2015, 80(3): 329-332. DOI:10.1016/j.maturitas.2014.12.018
[18]
Vaidya A, Forman JP, Hopkins PN, et al. 25-Hydroxyvitamin D is associated with plasma renin activity and the pressor response to dietary sodium intake in Caucasians[J]. J Renin Angiotensin Aldosterone Syst, 2011, 12(3): 311-319. DOI:10.1177/1470320310391922
[19]
Xie GQ, Lei DD, He HB, et al. Relationship between serum TGF-β1, OPG levels and osteoporotic risk in native Chinese women[J]. Clin Chim Acta, 2013, 423:116-121. DOI: 10.1016/j.cca.2013.04.019
[20]
Sun T, Chen M, Lin X, et al. The influence of osteoprotegerin genetic polymorphisms on bone mineral density and osteoporosis in Chinese postmenopausal women[J]. Int Immunopharmacol, 2014, 22(1): 200-203. DOI:10.1016/j.intimp.2014.06.023
[21]
Mohiti-Ardekani J, Soleymani-Salehabadi H, Owlia MB, et al. Relationships between serum adipocyte hormones (adiponectin, leptin, resistin), bone mineral density and bone metabolic markers in osteoporosis patients[J]. J Bone Miner Metab, 2014, 32(4): 400-404. DOI:10.1007/s00774-013-0511-4
Dincel VE, Sepici-Dincel A. The importance and the differences of bone morphogenetic proteins for osteoporotic hip fractures[J]. Acta Orthop Belg, 2014, 80(2): 216-221
[24]
Fodor D, Bondor C, Albu A, et al. The value of osteopontin in the assessment of bone mineral density status in postmenopausal women[J]. J Investig Med, 2013, 61(1): 15-21. DOI:10.2310/JIM.0b013e3182761264
[25]
Osako MK, Nakagami H, Koibuchi N, et al. Estrogen inhibits vascular calcification via vascular RANKL system: common mechanism of osteoporosis and vascular calcification[J]. Circ Res, 2010, 107(4): 466-475. DOI:10.1161/CIRCRESAHA.110.216846
[26]
Callegari A, Coons ML, Ricks JL, et al. Bone marrow- or vessel wall-derived osteoprotegerin is sufficient to reduce atherosclerotic lesion size and vascular calcification[J]. Arterioscler Thromb Vasc Biol, 2013, 33(11): 2491-2500. DOI:10.1161/ATVBAHA.113.301755
[27]
Secchiero P, Corallini F, Beltrami AP, et al. An imbalanced OPG/TRAIL ratio is associated to severe acute myocardial infarction[J]. Atherosclerosis, 2010, 210(1): 274-277. DOI:10.1016/j.atherosclerosis.2009.11.005
[28]
Witberg G, Ayers CR, Turer AT, et al. Relation of adiponectin to all-cause mortality, cardiovascular mortality, and major adverse cardiovascular events (from the Dallas Heart Study)[J]. Am J Cardiol, 2016, 117(4): 574-579. DOI:10.1016/j.amjcard.2015.11.067
[29]
Nagasawa H, Yokota C, Toyoda K, et al. High level of plasma adiponectin in acute stroke patients is associated with stroke mortality[J]. J Neurol Sci, 2011, 304(1-2): 102-106. DOI:10.1016/j.jns.2011.02.002
[30]
Panizo S, Cardus A, Encinas M, et al. RANKL increases vascular smooth muscle cell calcification through a RANK-BMP4-dependent pathway[J]. Circ Res, 2009, 104(9): 1041-1048. DOI:10.1161/CIRCRESAHA.108.189001
[31]
Derwall M, Malhotra R, Lai CS, et al. Inhibition of bone morphogenetic protein signaling reduces vascular calcification and atherosclerosis[J]. Arterioscler Thromb Vasc Biol, 2012, 32(3): 613-622. DOI:10.1161/atvbaha.111.242594
[32]
Takano M, Otsuka F, Matsumoto Y, et al. Peroxisome proliferator-activated receptor activity is involved in the osteoblastic differentiation regulated by bone morphogenetic proteins and tumor necrosis factor-α[J]. Mol Cell Endocrinol, 2012, 348(1): 224-232. DOI:10.1016/j.mce.2011.08.027
[33]
Yamaguchi A, Akashi T. Vascular calcification: mutual interaction between bone and blood vessel[J]. Clin Calcium, 2010, 20(11): 1669-1676. DOI:CliCa101116691676
[34]
Speer MY, Chien YC, Quan M, et al. Smooth muscle cells deficient in osteopontin have enhanced susceptibility to calcification in vitro[J]. Cardiovasc Res, 2005, 66(2): 324-333. DOI:10.1016/j.cardiores.2005.01.023
Seldenrijk A, Vogelzangs N, van Hout HP, et al. Depressive and anxiety disorders and risk of subclinical atherosclerosis Findings from the Netherlands Study of Depression and Anxiety (NESDA)[J]. J Psychosom Res, 2010, 69(2): 203-210. DOI:10.1016/j.jpsychores.2010.01.005
2017, Vol. 22 
